GENELUX Corp (GNLX) stock
GNLXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.24+0.24 (+12.00%)
Close on Nov 18, 2026Market cap $101.35MP/E –Yield –
Genelux net income
Net income is the profit left for shareholders after every expense, interest and tax.
Genelux's net income for the twelve months ending Jun 30, 2026 was -$35.60M. For fiscal 2025 it was -$32.15M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$32.15M | – |
| FY2024 | Dec 31, 2024 | -$29.87M | – |
| FY2023 | Dec 31, 2023 | -$28.30M | – |
| FY2022 | Dec 31, 2022 | -$5.21M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$9.47M | – |
| Q1 FY2026 | Mar 31, 2026 | -$8.93M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.25M | – |
| Q3 FY2025 | Sep 30, 2025 | -$7.95M | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.46M | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.49M | – |
| Q4 FY2024 | Dec 31, 2024 | -$8.98M | – |
| Q3 FY2024 | Sep 30, 2024 | -$6.47M | – |
| Q2 FY2024 | Jun 30, 2024 | -$6.58M | – |
| Q1 FY2024 | Mar 31, 2024 | -$7.85M | – |
| Q4 FY2023 | Dec 31, 2023 | -$6.77M | – |
| Q3 FY2023 | Sep 30, 2023 | -$5.35M | -208.9% |
| Q2 FY2023 | Jun 30, 2023 | -$5.82M | – |
| Q1 FY2023 | Mar 31, 2023 | -$10.36M | – |
| Q4 FY2022 | Dec 31, 2022 | -$3.50M | – |
| Q3 FY2022 | Sep 30, 2022 | $4.91M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.82M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.80M | – |
See a number that looks wrong?